



The dihydrorhodamine (DHR) test is the preferred method for detecting chronic granulomatous disease (CGD) and is known for its relative ease of use and ability to¹⁻³:

- Produce fewer false-negatives than the nitroblue tetrazolium test
- Distinguish between X-linked and autosomal recessive forms of CGD
- Detect X-linked carrier status (gp91^{phox} carriers)
- Quantitatively assess residual superoxide production

To order DHR Collection Kits, visit DHRTestKit.com/[ConfName]

Available to healthcare professionals free of charge from Horizon Therapeutics.







References: 1. Leiding JW, Holland SM. Chronic granulomatous disease. In: Pagon RA, Adam MP, Ardinger HH, et al., eds. *GeneReviews*. Seattle, WA: University of Washington, Seattle; 1993-2019. 2. Kuhns DB, Alvord WG, Heller T, et al. Residual NADPH oxidase and survival in chronic granulomatous disease. *N Engl J Med*. 2010;363(27):2600-2610. 3. Thomsen IP, Smith MA, Holland SM, Creech CB. A comprehensive approach to the management of children and adults with chronic granulomatous disease. *J Allergy Clin Immunol Pract*. 2016;4(6):1082-1088.

